

RESPONSE UNDER 37 C.F.R. § 1.116
EXPEDITED PROCEDURE
GROUP 1617
PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q64929

Shohei TANAKA, et al.

Appln. No.: 09/869,122

Group Art Unit: 1617

Confirmation No.: 2326

Examiner: Hui, S.

Filed: June 25, 2001

For: PHARMACEUTICAL COMPOSITIONS FOR TREATING BONE LESIONS IN
MULTIPLE MYELOMA

RESPONSE UNDER 37 C.F.R. § 1.116

ATTN: BOX AF
Commissioner for Patents
Washington, D.C. 20231

Sir:

This Amendment is responsive to the Office Action mailed March 27, 2002. The examiner set a three month period for the response. Attached hereto and herein incorporated by reference is a Petition for a two-month extension of time, making the due date for response August 27, 2002.

REMARKS

Claims 7 and 9-13 are all the claims pending in the application.

I. Rejection of claims under 35 U.S.C. § 103

At pages 2-4 of the Office Action, claims 7 and 9-13 are rejected under 35 U.S.C. §103(a) over Isomura et al. (US 4,990,503) in view of Shipman et al. (*Leukemia and Lymphoma*, 1998).

#14
N.E.
HKO
8-29-02